Literature DB >> 23436834

Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

Richard G Abramson1, Vandana G Abramson, Emily Chan, Leora Horn, Vicki L Keedy, William Pao, Jeffrey A Sosman.   

Abstract

OBJECTIVE: This article reviews important complications of targeted drug therapies for solid malignancies that can be identified on diagnostic imaging. Wherever possible, known or proposed mechanistic explanations for drug complications are emphasized.
CONCLUSION: Familiarity with the toxicity profiles of different targeted cancer therapies is important for identifying drug-related complications and for differentiating drug effects from disease progression. A mechanistic understanding may be useful for associating individual drugs with their complications and for predicting the complications of emerging agents.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23436834      PMCID： PMC3652983          DOI： 10.2214/AJR.12.9049

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  45 in total

1.  Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

Authors:  E Kapiteijn; A Brand; J Kroep; H Gelderblom
Journal:  Ann Oncol       Date:  2007-10       Impact factor: 32.976

2.  Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Authors:  Masahiko Ando; Isamu Okamoto; Nobuyuki Yamamoto; Koji Takeda; Kenji Tamura; Takashi Seto; Yutaka Ariyoshi; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

3.  Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know.

Authors:  Stephanie Anne Holler Howard; Katherine M Krajewski; Eavan Thornton; Jyothi P Jagannathan; Kevin O'Regan; James Cleary; Nikhil Ramaiya
Journal:  AJR Am J Roentgenol       Date:  2012-07       Impact factor: 3.959

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

Authors:  Yulia Bronstein; Chaan S Ng; Patrick Hwu; Wen-Jen Hwu
Journal:  AJR Am J Roentgenol       Date:  2011-12       Impact factor: 3.959

6.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 7.  Sirolimus-associated pulmonary toxicity.

Authors:  Phuong-Thu T Pham; Phuong-Chi T Pham; Gabriel M Danovitch; David J Ross; H Albin Gritsch; Elizabeth A Kendrick; Jennifer Singer; Tariq Shah; Alan H Wilkinson
Journal:  Transplantation       Date:  2004-04-27       Impact factor: 4.939

Review 8.  Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib.

Authors:  Xie Hong; Haesun Choi; Evelyne M Loyer; Robert S Benjamin; Jonathan C Trent; Chusilp Charnsangavej
Journal:  Radiographics       Date:  2006 Mar-Apr       Impact factor: 5.333

9.  Ipilimumab-induced hypophysitis: MR imaging findings.

Authors:  K J Carpenter; R D Murtagh; H Lilienfeld; J Weber; F R Murtagh
Journal:  AJNR Am J Neuroradiol       Date:  2009-05-27       Impact factor: 3.825

10.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245
View more
  9 in total

1.  [Treatment side effects and follow-up of malignant melanoma].

Authors:  T Stahl; C Loquai
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

Review 2.  Immune-related tumour response assessment criteria: a comprehensive review.

Authors:  Bhanusupriya Somarouthu; Susanna I Lee; Trinity Urban; Cheryl A Sadow; Gordon J Harris; Avinash Kambadakone
Journal:  Br J Radiol       Date:  2018-02-14       Impact factor: 3.039

Review 3.  Hydrogen Sulfide Biology and Its Role in Cancer.

Authors:  Saadullah Khattak; Mohd Ahmar Rauf; Nazeer Hussain Khan; Qian-Qian Zhang; Hao-Jie Chen; Pir Muhammad; Mohammad Azam Ansari; Mohammad N Alomary; Muhammad Jahangir; Chun-Yang Zhang; Xin-Ying Ji; Dong-Dong Wu
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

4.  CD44 and CD74: The promising candidates for molecular targeted therapy in oral squamous cell carcinoma.

Authors:  Pouyan Amini Shakib; Fereshteh Ensani; Afshin Abdirad; Bahareh Valizadeh; Maryam Seyedmajidi; Shima Sum
Journal:  Dent Res J (Isfahan)       Date:  2015 Mar-Apr

5.  A rare case of osteonecrosis of the jaw related to imatinib.

Authors:  Massimo Viviano; Marco Rossi; Serena Cocca
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2017-04-25

6.  Interstitial Lung Disease Induced by Pazopanib Treatment.

Authors:  Shotaro Ide; Noriho Sakamoto; Shintaro Hara; Atsuko Hara; Tomoyuki Kakugawa; Yoichi Nakamura; Yoji Futsuki; Koichi Izumikawa; Yuji Ishimatsu; Katsunori Yanagihara; Hiroshi Mukae
Journal:  Intern Med       Date:  2017-01-01       Impact factor: 1.271

7.  Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer.

Authors:  Laura Ximena Kattah Martinez; Lisseth Fernanda Marín Carrillo; Leonardo Rojas Melo
Journal:  Eur Thyroid J       Date:  2018-04-25

8.  Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.

Authors:  Guillermo de Velasco; Kathryn P Gray; Lana Hamieh; Yuksel Urun; Hallie A Carol; Andre P Fay; Sabina Signoretti; David J Kwiatkowski; David F McDermott; Matthew Freedman; Mark M Pomerantz; Toni K Choueiri
Journal:  Eur Urol Focus       Date:  2016-04-23

9.  Pneumatosis intestinalis in oncologic patients: when should the radiologist not be afraid?

Authors:  Claudia Sassi; Milena Pasquali; Giancarlo Facchini; Alberto Bazzocchi; Giuseppe Battista
Journal:  BJR Case Rep       Date:  2016-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.